Astaxanthin

What the evidence says

Astaxanthin is a carotenoid found in the microalga Haematococcus pluvialis and used in oral supplements. Its antioxidant activity helps explain research interest, but laboratory mechanisms do not establish a health benefit. This entry evaluates oral supplementation: the available skin and metabolic studies do not demonstrate slower human aging or longer life.^[1][5]

A 2021 meta-analysis pooled eight randomized skin studies involving 293 participants. Oral supplementation improved measured moisture and elasticity compared with control, but did not significantly reduce wrinkle depth. Results varied substantially for elasticity, and small samples and imperfect study methods limit how confidently these measurements predict a noticeable cosmetic benefit. A separate systematic review found that participants were often healthy Japanese women and that many studies had commercial funding.^[1][2]

In a manufacturer-funded, placebo-controlled trial, 23 healthy Japanese adults were recruited to take 4 mg daily or placebo over ten weeks. Testing after nine weeks found an increase in the ultraviolet dose needed to cause redness and less moisture loss after irradiation. This small experiment does not establish protection against skin cancer or show that a supplement can replace sunscreen and other sun protection.^[3]

Metabolic findings need similar restraint. A 24-week randomized trial of 12 mg daily in adults with prediabetes and dyslipidaemia reported reductions in LDL and total cholesterol, but its primary insulin-sensitivity endpoint did not meet the prespecified significance threshold. A 2026 meta-analysis of nine trials involving 403 people with prediabetes or type 2 diabetes reported improvements in some glucose and lipid measures, without significant changes in weight, BMI, or HOMA-IR, an estimate of insulin resistance. Substantial variation between trials and possible publication bias weaken confidence; these results do not prove fewer cardiovascular events or benefits in healthy adults.^[4][5]

Studied doses are not a recommended regimen. EFSA's 2020 assessment concluded that 8 mg daily from supplements was safe for adults under its model of combined supplement and dietary exposure. That conclusion does not establish the safety of higher trial doses or indefinite use of every formulation. Its 2025 review of additional food uses also stressed cumulative exposure: children and adolescents should not consume the proposed astaxanthin-enriched foods and astaxanthin supplements on the same day.^[6][7]

The skin review reported no serious adverse events in its included studies, but short, small trials cannot reliably detect uncommon harms. The 2026 metabolic review also identified inadequate adverse-effect reporting. A published case described extensive bruising and an INR above 10, indicating excessive anticoagulation, after astaxanthin was added to warfarin in a woman also taking aspirin and other medicines. One case cannot establish how often an interaction occurs or prove causality, but it supports caution and medication review before combining the supplement with warfarin.^[2][5][8]

The Emerging rating applies to possible short-term skin benefits and selected metabolic markers. Stronger claims about wrinkle reversal, disease prevention, or longevity are not established by these studies. Larger independent trials with meaningful outcomes and better safety follow-up are needed before routine supplementation can be supported on that basis.^[1][5]